Immunophenotyping of Orthotopic Homograft (Syngeneic) of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry
October 9th, 2018
12K views
The experimental procedure on the immunophenotyping of murine orthotopic PDAC homografts aims at profiling the tumor immuno-microenvironment. Tumors are orthotopically implanted via surgery. Tumors of 200–600 mm3 in size were harvested and dissociated to prepare single-cell suspensions, followed by multi-immune marker FACS analysis using different fluorescently-labeled antibodies.
Overview
This study focuses on the immunophenotyping of murine orthotopic pancreatic ductal adenocarcinoma (PDAC) homografts to profile the tumor immuno-microenvironment. The tumors are surgically implanted and analyzed using multi-immune marker FACS.
Key Study Components
Area of Science
- Immunology
- Oncology
- Translational Research
Background
- Immunophenotyping helps identify different immune lineages.
- It can be applied to various murine models.
- Monitoring body weight and tumor volume is crucial for experimental accuracy.
- Protocols ensure proper handling and euthanasia of animals.
Purpose of Study
- To profile the tumor immuno-microenvironment in PDAC models.
- To utilize FACS analysis for immune marker identification.
- To establish a reliable method for studying tumor immunity.
Methods Used
- Orthotopic implantation of PDAC tumors in murine models.
- Harvesting and dissociating tumors to prepare single-cell suspensions.
- Multi-immune marker FACS analysis with fluorescently-labeled antibodies.
- Monitoring body weight and tumor volume during the study.
Main Results
- Successful profiling of the tumor immuno-microenvironment.
- Identification of key immune markers associated with PDAC.
- Demonstration of the technique's applicability across murine models.
- Establishment of a protocol for tumor handling and analysis.
Conclusions
- The study provides insights into the immune landscape of PDAC.
- FACS analysis is effective for immunophenotyping in murine models.
- Findings may inform future therapeutic strategies targeting tumor immunity.
Frequently Asked Questions
What is immunophenotyping?
Immunophenotyping is a technique used to analyze the types and characteristics of immune cells in a sample.
Why use murine models for PDAC research?
Murine models closely mimic human disease, allowing for better understanding and testing of therapies.
What is FACS analysis?
Fluorescence-activated cell sorting (FACS) is a method for sorting a mixture of cells into different populations based on their light scattering and fluorescent characteristics.
How are tumors implanted in murine models?
Tumors are orthotopically implanted via surgical procedures to study their growth and interaction with the host immune system.
What precautions are taken during the procedure?
Protocols include monitoring body weight, tumor volume, and ensuring proper euthanasia and handling of the animals.
What are the implications of this research?
The findings can lead to improved understanding of tumor immunity and potential therapeutic targets in PDAC.
Executive Industry Relevance
Immunophenotyping of orthotopic syngeneic murine pancreatic ductal adenocarcinoma models enables detailed profiling of the tumor immune microenvironment, a critical factor in predicting immunotherapy response. This approach supports target validation by quantifying immune cell infiltration and subset distribution, informing mechanistic de-risking in oncology drug discovery. The method provides predictive confidence for translational continuity from discovery to preclinical evaluation.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses by characterizing tumor-infiltrating lymphocyte and myeloid populations in PDAC models.
- Operational Value: Supports functional target validation through multi-color FACS quantification of immune subsets, reducing mechanistic ambiguity.
- Predictive Value: Facilitates portfolio triage by identifying immune phenotypes associated with tumor progression or therapy resistance.
Screening & Assay Development
- Scientific Value: Prepares validated single-cell suspensions from dissociated tumors for reproducible immune profiling across experimental conditions.
- Operational Value: Standardizes immune cell isolation and staining workflows, ensuring assay consistency and scalability for high-content screening.
- Predictive Value: Generates quantitative immune readouts that enable reliable compound evaluation in immunomodulatory discovery programs.
Translational & Preclinical Research
- Scientific Value: Aligns with disease-relevant systems by comparing immune profiles in orthotopic versus subcutaneous tumors, reflecting human PDAC microenvironment complexity.
- Operational Value: Ensures translational continuity by providing standardized immune phenotyping from discovery through preclinical validation stages.
- Predictive Value: Supports risk-adjusted advancement decisions by identifying immune biomarkers correlated with tumor growth and infiltration patterns.
Pipeline & Workflow Integration
The method integrates into the discovery continuum by enabling immune profiling after tumor harvest and dissociation, informing lead identification through mechanistic insights into tumor-immune interactions.
- Discovery Biology: Supports hypothesis testing and pathway clarification by quantifying immune cell lineages in the tumor microenvironment.
- Screening: Delivers assay readiness and quantitative outputs via multi-color FACS, enabling comparison of immune responses across treatment groups.
- Analytics: Provides statistical measurements of immune cell percentages and absolute counts, facilitating data-driven condition comparisons.
- Translational Research: Connects to preclinical continuity through standardized immune profiling applicable to both orthotopic and subcutaneous models.
- Enterprise Reuse: Functions as a reusable immunophenotyping platform applicable across diverse murine oncology models.
Operational & Enterprise Impact
- Scientific Value: Predictive confidence in target validation through reduction of mechanistic ambiguity in tumor-immune interactions.
- Operational Value: Standardization, reproducibility, and scalability of immune cell isolation and multi-parameter FACS analysis.
- Strategic Value: Improved go/no-go decisions, capital efficiency, and reduced late-stage biological risk via early immune phenotype stratification.
- Portfolio Impact: Risk-adjusted prioritization and advancement decisions based on quantitative immune infiltration metrics.
Implementation Considerations
- Requires expertise in murine tumor surgery, tissue dissociation, and multi-color flow cytometry panel design.
- Dependent on tissue dissociator equipment, flow cytometers with sufficient laser and detector capacity, and validated antibody panels.
- Necessitates cross-team standardization of tumor harvest timing, digestion protocols, and gating strategies for reproducible immune profiling.
- Involves adaptation considerations when applying the protocol to different tumor models or immune cell panels.
- Limited by tumor size constraints (400–600 mm³) and viability thresholds post-dissociation, as noted in the source material.
Biopharma FAQs
Why does null hypothesis testing matter for target validation in immunophenotyping?
Null hypothesis testing determines whether observed differences in immune cell infiltration between orthotopic and subcutaneous tumors are statistically significant, supporting confident target validation decisions.
How does independent variable isolation fit the discovery pipeline in tumor immune profiling?
Isolating the tumor implantation site (orthotopic vs subcutaneous) as the independent variable enables clear attribution of immune phenotype differences to microenvironmental context in discovery workflows.
What quantitative dependent variable measurements enable immune subset analysis in FACS?
Dependent variables include absolute cell counts and relative percentages of tumor-infiltrating immune subsets (e.g., B cells, TAMs) obtained via multi-color FACS, enabling quantitative comparison.
Why do replication requirements matter for cross-functional collaboration in immunophenotyping studies?
Replication ensures consistent immune profiling results across experiments, allowing discovery, preclinical, and translational teams to rely on standardized data for decision-making.
What statistical analysis capabilities are required before implementing multi-color FACS for immune profiling?
Implementation requires capability to perform compensation controls, quadrant gating, and statistical comparison of immune subset frequencies between experimental groups using flow cytometry data.
Chapters in this video
0:04
Title
0:33
Preparation for Tumor Transplantation
1:40
Surgical Operation for Orthotopic Implantation
2:58
Tumor Tissue Dissociation and Single Cell Preparation
5:01
Flow Data Acquisition
6:46
Results: Comparison of Orthotopic and Subcutaneous Implantation of Pancreatic Ductal Adenocarcinoma
8:04
Conclusion
